MTA1、VEGF在化疗后骨肉瘤组织中的表达及其相关性  

Relation between MTA1 and VEGF Combinative Expression for Prognosis in Osteosarcoma Patients after Chemotherapy

作　　者：杨阳[1] 步国强 于秀淳[3] 

机构地区：[1]第二军医大学研究生院,上海200433 [2]山东省菏泽市市立医院骨科 [3]济南军区总医院骨病科

出　　处：《肿瘤防治研究》2011年第2期155-158,共4页Cancer Research on Prevention and Treatment

摘　　要：目的探讨转移相关蛋白(Mta-1)和血管内皮生长因子(VEGF)在化疗后骨肉瘤组织中表达与化疗后骨肉瘤患者预后之间的关系。方法采用免疫组织化学SP法,检测31例化疗后骨肉瘤组织中MTA1与VEGF的表达。并应用统计学方法分析其与预后的相关性。结果统计学分析显示化疗后骨肉瘤组织中MTA1与VEGF表达与骨肉瘤患者预后显著相关(P<0.05),MTA1与VEGF联合检测对化疗后骨肉瘤患者预后更有指导意义。结论 VEGF与MTA1均为阴性预后较好;VEGF、MAT1均为阳性预后较差。联合检测MTA1与VEGF可以用于评估化疗后骨肉瘤患者的预后。Objective To explore the role of metastasis associated protein-1（Mta-1）and vascular endothelial growth factor（VEGF） expression in the occurrence and development of osteosarcoma after chemotherapy.And to investigate the relation between MTA1 and VEGF combinative expression and the prognosis in osteosarcoma patients after chemotherapy.Methods SP immunohistochemical technique was used to detect the expression of MTA1 and VEGF in the residual tumor cells from 31 osteosarcoma patients after chemotherapy.Results There were statistical significance of MTA1 and VEGF combinative expression for the prognosis in osteosarcoma patients after chemotherapy.Conclusion Both negative of MTA1 and VEGF are better for the prognosis in osteosarcoma patients after chemotherapy.While positive expression for both of them means poor prognosis.The results indicate that Mta-1 and VEGF combinative expression could be used to assess the prognosis of patients with osteosarcoma after chemotherapy.

关 键 词：骨肉瘤 新辅助化疗 MTA1 VEGF 

分 类 号：R738.1[医药卫生—肿瘤]